Coherus Biosciences | CHRS - Gross Profit On Sales


Coherus Biosciences reported $8.7M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
AbbVie USD 14.39B 1.85B Jun/2026
Acadia Pharmaceuticals USD 243.27M 14.49M Mar/2026
Akebia Therapeutics USD 47.28M 1.7M Dec/2025
ALKERMES USD 375.31M 43.98M Jun/2026
Alnylam Pharmaceuticals USD 992.69M 167.68M Jun/2026
Amarin USD 23.17M 961K Dec/2025
Amgen USD 6.89B 415M Dec/2025
Baxter International USD 1.14B 251M Jun/2026
Biogen USD 2.12B 307M Jun/2026
BioMarin Pharmaceutical USD 571.21M 141.8M Mar/2026
Bristol-Myers Squibb USD 9.26B 1.19B Jun/2026
Coherus Biosciences USD 8.7M 853K Dec/2025
Eli Lilly USD 15.92B 1.33B Dec/2025
Fujifilm JPY 376.67B 29.16B Mar/2026
Gilead Sciences USD 5.52B 791M Mar/2026
Ironwood Pharmaceuticals USD 85.24M 44.1M Jun/2025
Merck USD 10.85B 2.57B Dec/2025
Myriad Genetics USD 146.8M 3M Dec/2025
Pacira USD 126.64M 15.61M Mar/2026
Perrigo USD 325.5M 36.7M Mar/2026
Pfizer USD 11.04B 1.24B Mar/2026
PTC Therapeutics USD 232.94M 84.56M Mar/2026
Regeneron Pharmaceuticals USD 3.71B 778.2M Jun/2026
Sarepta Therapeutics USD 621.34M 577.79M Mar/2026
Teva Pharmaceutical Industries USD 2.15B 45M Jun/2026
Vertex Pharmaceuticals USD 2.6B 121.7M Mar/2026
Xencor USD 21M 22.61M Sep/2025
Zoetis USD 1.62B 20M Mar/2026